Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Guidance and Visibility -- Ignore unavailable to you. Want to Upgrade?

To: MJ who wrote (193398)	5/18/2009 3:34:21 PM
From: BarbaraT	Read Replies (1) \| Respond to of 208838

MJ - the CEO of Mannkind, had a couple other companies which were sold to Medtronics (an implantable insulin pump) and I forget what the other company was that was sold - but also dealt with Type 2 Diabetes. He really has been a pioneer in the field of diabetes with his delivery systems for insulin. here is the current news - this is an inhalable insulin. May 18 (Reuters) - MannKind Corp (MNKD.O) said the U.S. health regulators accepted the new drug application for its inhaled-insulin product, Afresa, sending its shares up as much as 24 percent. The company is seeking approval of Afresa for use in adults with type 1 or type 2 diabetes mellitus for the treatment of hyperglycemia, or high blood sugar. The U.S. Food and Drug Administration's acceptance of the Afresa application comes after several large drugmakers have exited the space due to weak demand and safety concerns. Pfizer Inc (PFE.N), which expected its inhaled insulin Exubera to be a $2 billion-a-year blockbuster, had to withdraw the product from the U.S. market in 2007 due to weak demand. Exubera was also dogged by concerns about lung safety and the inconvenience of the bulky device used to administer it.